Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 7/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873467 | 0.91 | CARM1 (0.49) | CARM1PRMT6DRD2DRD3GRIN2A | |
| SCHEMBL4865285 | 0.86 | CARM1 (0.49) | CARM1PRMT6GRIN2AGRIN2B | |
| SCHEMBL4876611 | 0.84 | CARM1 (0.48) | CARM1PRMT6GRIN2AGRIN2B | |
| SCHEMBL4871992 | 0.84 | CARM1 (0.48) | CARM1PRMT6GRIN2AGRIN2B | |
| SCHEMBL4873481 | 0.82 | CARM1 (0.47) | CARM1PRMT6DRD2DRD3GRIN2A | |
| SCHEMBL14082390 | 0.82 | CARM1 (0.43) | CARM1PRMT6DRD2DRD3GRIN2A | |
| SCHEMBL4874025 | 0.80 | CARM1 (0.43) | CARM1PRMT6GRIN2AGRIN2BDRD4 | |
| SCHEMBL4866579 | 0.80 | CARM1 (0.43) | CARM1PRMT6GRIN2AGRIN2BDRD4 | |
| SCHEMBL4870804 | 0.80 | GRIN2A (0.54) | CARM1PRMT6GRIN2AGRIN2B | |
| SCHEMBL4868790 | 0.79 | CARM1 (0.42) | CARM1PRMT6DRD2GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7408067-B2 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK + CO., INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| EP-1467986-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062224-A1 | AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS | ELI LILLY AND COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070520-A1 | Aza-cyclic compounds as modulators of acetylcholine receptors | CHRNG, CHRNA4, CHRNB4 | CARM1 1203/4885PRMT6 592/4885DRD2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.